Table 4.
KEGG pathway analysis of miR-199a-3p and miR-151a-3p targets. The FDR-adjusted p-value (Benjamini–Hochberg), p < 0.05 was considered as statistically significant.
| Pathway | No. of Overlapping Genes | Adjusted p-Value | Genes |
|---|---|---|---|
| PI3K-Akt signalling pathway | 24 | 1.37 × 10−5 | YWHAE;ITGA3;INSR;ITGA1;FN1;PTEN;PPP2R2A;TSC1;LPAR4;FGF2;THBS1;MTOR;GHR;FGF7;PPP2R5E;ERBB4;AKT3;DDIT4;CHAD;ITGA8;ITGB8;PKN2;ITGA6;TP53 |
| MAPK signalling pathway | 19 | 2.78 × 10−4 | MAP3K2;DUSP5;INSR;NLK;FGF2;RPS6KA3;RPS6KA6;FGF7;RPS6KA5;ERBB4;TAOK1;AKT3;GNA12;TAB2;TP53;LAMTOR3;CRK;MAP3K4;MAP3K5 |
| Regulation of actin cytoskeleton | 16 | 2.78 × 10−4 | ITGA3;ITGA1;FN1;LPAR4;FGF2;MYLK4;GNA13;FGF7;CFL2;GNA12;ITGA8;ITGB8;ITGA6;CRK;PFN2;PAK4 |
| Central carbon metabolism in cancer | 8 | 2.72 × 10−3 | PDHA1;AKT3;PTEN;TP53;HIF1A;HK2;MTOR;GLS |
| Sphingolipid signalling pathway | 10 | 3.70 × 10−3 | GNA13;PPP2R5E;PRKCE;AKT3;GNA12;PTEN;PPP2R2A;PLCB1;TP53;MAP3K5 |
| Focal adhesion | 13 | 4.19 × 10−3 | ITGA3;ITGA1;FN1;PTEN;THBS1;MYLK4;AKT3;CHAD;ITGA8;ITGB8;ITGA6;CRK;PAK4 |
| ECM−receptor interaction | 8 | 6.54 × 10−3 | ITGA3;ITGA1;CHAD;ITGA8;FN1;ITGB8;ITGA6;THBS1 |
| MicroRNAs in cancer | 16 | 6.54 × 10−3 | PRKCE;DNMT3A;PTEN;HMGA2;THBS1;MTOR;GLS;FOXP1;RPS6KA5;MMP16;DDIT4;TIMP3;ZFPM2;TP53;CRK;PAK4 |
| Dilated cardiomyopathy | 8 | 9.34 × 10−3 | ITGA3;ITGA1;ITGA8;ATP2A2;ITGB8;ITGA6;ADRB1;SLC8A1 |
| Phospholipase D signalling pathway | 10 | 9.34 × 10−3 | GRM3;GNA13;INSR;AKT3;GNA12;TSC1;LPAR4;PLCB1;MTOR;RAPGEF4 |
| mTOR signalling pathway | 10 | 1.00 × 10−2 | RPS6KA3;RPS6KA6;INSR;AKT3;DDIT4;PTEN;TSC1;LAMTOR3;LPIN2;MTOR |
| Insulin resistance | 8 | 1.38 × 10−2 | RPS6KA3;RPS6KA6;PRKCE;INSR;AKT3;PTEN;PTPRF;MTOR |
| cGMP-PKG signalling | 10 | 1.47 × 10−2 | GNA13;PRKCE;INSR;AKT3;GNA12;ATP2A2;ADRB1;PLCB1;SLC8A1;MYLK4 |
| Hyperthrophic cardiomyopathy | 7 | 1.73 × 10−2 | ITGA3;ITGA1;ITGA8;ATP2A2;ITGB8;ITGA6;SLC8A1 |
| TGF-beta signalling pathway | 7 | 1.84 × 10−2 | GREM1;SMAD2;TGIF2;ACVR1C;THBS1;ACVR2B;ACVR2A |